Raphael Szalat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raphael Szalat has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Nikhil C. Munshi
Dana-Farber Cancer Institute
11 shared publications - Mehmet Kemal Samur
Department of Data Science, Dana Farber Cancer Institute, Boston, USA
9 shared publications - Anaïs Schavgoulidze
Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
8 shared publications - Annamaria Gulla
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
8 shared publications - Charles B. Epstein
Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
8 shared publications - Eugenio Morelli
Candiolo Cancer Institute, Torino, Italy
8 shared publications
Latest Publications
- 12 October 2026
- Published by Wiley in American Journal of Hematology
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy
Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti‐CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited. Using data from 25 U.S.‐based academic cancer centers, we conducted two target trials examining the association between early receipt of PLEX or early receipt of daratumumab and kidney recovery in patients with newly diagnosed LCCN. Kidney recovery was defined as being alive, not on kidney replacement therapy, and with an improvement of at least one stage of AKI severity, all assessed at 90 days. Secondary outcomes included kidney recovery at 60 and 180 days. Logistic regression with propensity score overlap weights was used to adjust for confounders. Of 549 eligible patients for the PLEX target trial, 158 (28.8%) received PLEX. There was no association between PLEX and kidney recovery at 90 days (OR 1.48, 95% CI: 0.96–2.30). However, in subgroup analyses, PLEX was associated with higher odds of kidney recovery at 90 days among patients with newly diagnosed multiple myeloma compared to those with relapsed disease, as well as higher odds of kidney recovery among those with Stage 3 versus Stage 1 or 2 AKI at the time of LCCN diagnosis. Of 474 patients eligible for the daratumumab target trial, 136 (28.7%) received daratumumab. Daratumumab was not associated with kidney recovery at 90 days (OR 1.46, 95% CI: 0.84–2.55). Thus, in this multicenter cohort study, neither PLEX nor daratumumab was associated with kidney recovery at 90 days.
- 12 October 2026
- Published by Wiley in American Journal of Hematology
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy
Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti‐CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited. Using data from 25 U.S.‐based academic cancer centers, we conducted two target trials examining the association between early receipt of PLEX or early receipt of daratumumab and kidney recovery in patients with newly diagnosed LCCN. Kidney recovery was defined as being alive, not on kidney replacement therapy, and with an improvement of at least one stage of AKI severity, all assessed at 90 days. Secondary outcomes included kidney recovery at 60 and 180 days. Logistic regression with propensity score overlap weights was used to adjust for confounders. Of 549 eligible patients for the PLEX target trial, 158 (28.8%) received PLEX. There was no association between PLEX and kidney recovery at 90 days (OR 1.48, 95% CI: 0.96–2.30). However, in subgroup analyses, PLEX was associated with higher odds of kidney recovery at 90 days among patients with newly diagnosed multiple myeloma compared to those with relapsed disease, as well as higher odds of kidney recovery among those with Stage 3 versus Stage 1 or 2 AKI at the time of LCCN diagnosis. Of 474 patients eligible for the daratumumab target trial, 136 (28.7%) received daratumumab. Daratumumab was not associated with kidney recovery at 90 days (OR 1.46, 95% CI: 0.84–2.55). Thus, in this multicenter cohort study, neither PLEX nor daratumumab was associated with kidney recovery at 90 days.
- 1 September 2026
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 32 (5)
Tailoring Therapy for Frail and Elderly Myeloma Patients
Multiple myeloma is a plasma cell malignancy associated with heterogeneous clinical outcomes. The majority of patients are diagnosed during their seventh decade and often present with age-related comorbidities and organ dysfunction. Myeloma therapeutic landscape is rapidly evolving with the introduction of immune-based therapies, including monoclonal and bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies targeting CD38, BCMA, and GPRC5D. These novel therapies have led to deeper and more durable responses and have raised the possibility of functional or definitive cure. However, older and frail patients continue to experience poorer outcomes, higher toxicity rates, and substantial treatment attrition, representing a major unmet clinical challenge. In this review, we discuss current approaches to the assessment and management of frailty in patients with multiple myeloma, with a focus on optimizing frontline therapy and treatment at relapse in the era of the possible achievement of a cure. We highlight emerging data on cellular therapies in this population and the importance of individualized, goal-directed treatment strategies aimed at balancing efficacy, tolerability, and quality of life.
- 1 September 2026
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 32 (5)
Tailoring Therapy for Frail and Elderly Myeloma Patients
Multiple myeloma is a plasma cell malignancy associated with heterogeneous clinical outcomes. The majority of patients are diagnosed during their seventh decade and often present with age-related comorbidities and organ dysfunction. Myeloma therapeutic landscape is rapidly evolving with the introduction of immune-based therapies, including monoclonal and bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies targeting CD38, BCMA, and GPRC5D. These novel therapies have led to deeper and more durable responses and have raised the possibility of functional or definitive cure. However, older and frail patients continue to experience poorer outcomes, higher toxicity rates, and substantial treatment attrition, representing a major unmet clinical challenge. In this review, we discuss current approaches to the assessment and management of frailty in patients with multiple myeloma, with a focus on optimizing frontline therapy and treatment at relapse in the era of the possible achievement of a cure. We highlight emerging data on cellular therapies in this population and the importance of individualized, goal-directed treatment strategies aimed at balancing efficacy, tolerability, and quality of life.
- 29 March 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2252-2255
Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis
- 29 March 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2252-2255
Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Differentially expressed proteins in ID2 OE cells (24 hours after induction with doxycycline).
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Differentially expressed proteins in ID2 OE cells (24 hours after induction with doxycycline).
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
MAGeCK analysis for CRISPRa screen.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
MAGeCK analysis for CRISPRa screen.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Transcription factor footprinting and chromatin accessibility in MM cells overexpressing ID2, obtained through ATAC-seq analysis.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Transcription factor footprinting and chromatin accessibility in MM cells overexpressing ID2, obtained through ATAC-seq analysis.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S6 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Supplementary Figure S1. Discovery of ID2 as a putative tumor suppressor in MM. Supplementary Figure S2. ID2 expression causes cell cycle arrest in MM cells. Supplementary Figure S3. Induced ID2 expression in MM cells is associated with senescence-like features. Supplementary Figure S4. TCF3 is a highly expressed selective dependency in MM cells. Supplementary Figure S5. Depletion of TCF3 phenocopies effects of ID2 overexpression in MM cells. Supplementary Figure S6. The bone marrow milieu has a role in supporting TCF3 activity in MM.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S6 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Supplementary Figure S1. Discovery of ID2 as a putative tumor suppressor in MM. Supplementary Figure S2. ID2 expression causes cell cycle arrest in MM cells. Supplementary Figure S3. Induced ID2 expression in MM cells is associated with senescence-like features. Supplementary Figure S4. TCF3 is a highly expressed selective dependency in MM cells. Supplementary Figure S5. Depletion of TCF3 phenocopies effects of ID2 overexpression in MM cells. Supplementary Figure S6. The bone marrow milieu has a role in supporting TCF3 activity in MM.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Differentially expressed genes in ID2 OE cells (24 hours after induction with doxycycline).
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Differentially expressed genes in ID2 OE cells (24 hours after induction with doxycycline).
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Peptides identified by mass spectrometry after co-IP of FLAG-ID2 in MM cell lines
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Peptides identified by mass spectrometry after co-IP of FLAG-ID2 in MM cell lines
- 17 October 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (1) , 129-141
ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Transcription factors and their cofactors are major and selective nononcogene dependencies in multiple myeloma cells. By performing a gain-of-function perturbation screen in human multiple myeloma cell lines, we identified the inhibitor of DNA binding (ID) genes as putative suppressors of multiple myeloma cell fitness. Among them, ID2 was found to be downregulated in multiple myeloma patient cells and acted as a tumor suppressor by directly binding and repressing the basic helix-loop-helix factor TCF3, also known as E2A. Lower ID2 expression in multiple myeloma cells conferred a proliferative advantage by increasing TCF3 activity, leading to a dependency on this transcription factor. In contrast, ID2 overexpression reduced TCF3 binding to DNA, which resulted in cell-cycle arrest and a halt in multiple myeloma cell proliferation. The myeloma bone marrow milieu supported this process by further decreasing the expression of ID2 and enhancing TCF3 activity, partly via IL6, revealing a mechanism by which the tumor microenvironment affects multiple myeloma cell behavior. Significance: Multiple myeloma cells exploit the oncogenic and proliferative potential of TCF3 by downregulating the transcriptional regulator ID2, a process facilitated by the bone marrow microenvironment.
- 17 October 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (1) , 129-141
ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Transcription factors and their cofactors are major and selective nononcogene dependencies in multiple myeloma cells. By performing a gain-of-function perturbation screen in human multiple myeloma cell lines, we identified the inhibitor of DNA binding (ID) genes as putative suppressors of multiple myeloma cell fitness. Among them, ID2 was found to be downregulated in multiple myeloma patient cells and acted as a tumor suppressor by directly binding and repressing the basic helix-loop-helix factor TCF3, also known as E2A. Lower ID2 expression in multiple myeloma cells conferred a proliferative advantage by increasing TCF3 activity, leading to a dependency on this transcription factor. In contrast, ID2 overexpression reduced TCF3 binding to DNA, which resulted in cell-cycle arrest and a halt in multiple myeloma cell proliferation. The myeloma bone marrow milieu supported this process by further decreasing the expression of ID2 and enhancing TCF3 activity, partly via IL6, revealing a mechanism by which the tumor microenvironment affects multiple myeloma cell behavior. Significance: Multiple myeloma cells exploit the oncogenic and proliferative potential of TCF3 by downregulating the transcriptional regulator ID2, a process facilitated by the bone marrow microenvironment.